文献速递消化、代谢与肾脏急症重症综合管理与镇静镇痛

安德沙α在口服Xa因子抑制剂相关消化道出血管理中的真实世界应用

Real world utilization of Andexanet alfa in the management of oral factor Xa inhibitor-associated gastrointestinal bleeding.
PubMed 文献 · Am J Emerg Med · 2023-07-24
一句话结论回顾性多中心单臂真实世界观察:22例Xa因子抑制剂相关消化道出血患者接受安德沙α后,69%止血良好,30天动脉血栓事件率9%。

该回顾性队列研究纳入2018年7月至2021年2月连续接受安德沙α(AA)治疗Xa因子抑制剂(FXaI)相关消化道出血(GIB)的患者22例,主要评估真实世界使用情况及止血效果。止血效果按12小时校正血红蛋白较基线下降程度分为优秀(下降<10%)、良好(下降≤20%)和差(下降>20%、需额外凝血干预>2单位或重复血红蛋白前死亡)。结果显示止血优秀46%(n=10)、良好23%(n=5)、差32%(n=7);优秀/良好组与差组接受红细胞输注量无统计学显著差异;30天内2例(9%)发生动脉血栓事件。作者结论认为多数患者止血良好,但缺乏对照组限制结论强度。

要点

  • 22例FXaI相关GIB患者接受AA后,止血优秀46%(n=10)、良好23%(n=5)、差32%(n=7),即69%止血良好。
  • 止血优秀/良好组红细胞输注中位数2单位(IQR 1-2),差组中位数4单位(IQR 1.5-4.5),两组无统计学显著差异。
  • 30天内2例(9%)发生动脉血栓事件。
  • 59%(n=13)患者使用阿哌沙班,64%(n=14)抗凝指征为心房颤动,50%(n=11)为上消化道出血。
  • 该研究为多中心、单臂、真实世界观察性分析,缺乏对照组限制结论强度。

适用人群与场景

  • 接受安德沙α(AA)治疗Xa因子抑制剂(FXaI)相关消化道出血(GIB)的连续患者,纳入时间为2018年7月至2021年2月。
  • 22例患者中64%为男性,中位年龄76岁(IQR 67, 80);59%(n=13)使用阿哌沙班,64%(n=14)抗凝指征为心房颤动;50%(n=11)为上消化道出血。

诊断标准与关键阈值

  • 止血效果基于12小时校正血红蛋白较基线下降程度分级:优秀为下降<10%,良好为下降≤20%,差为下降>20%、需额外凝血干预>2单位或重复血红蛋白前死亡。

处置流程与药物剂量

  • 患者接受安德沙α(AA)治疗FXaI相关GIB;原文未给出AA的具体剂量、给药途径和频次。

研究设计与关键结果

  • 研究类型:回顾性队列研究,多中心、单臂、真实世界观察性分析,纳入连续患者22例。
  • 主要终点止血效果:优秀46%(n=10)、良好23%(n=5)、差32%(n=7)。
  • 次要终点红细胞输注:止血优秀/良好组中位数2单位(IQR 1-2),止血差组中位数4单位(IQR 1.5-4.5),两组无统计学显著差异。
  • 安全性:30天内2例(9%)发生动脉血栓事件。
  • 基线:中位初始血红蛋白7.5 g/dL(IQR 6.4, 8.8)。

证据类型、等级与局限

  • 证据类型:回顾性队列研究(多中心、单臂、真实世界观察性分析)。
  • 局限:缺乏对照组限制结论强度(原文结论中自述)。

对床旁实践的改变

  • 作者结论认为,在FXaI相关GIB患者中,多数患者接受AA后止血良好;30天血栓事件率为9%;缺乏对照组限制结论强度。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Andexanet alfa (AA) is approved for reversal of factor Xa inhibitor (FXaI) bleeds; however, there are limited reports of its use for gastrointestinal bleeding (GIB) in real-world populations. The objective of this study was to report real-world utilization and evaluation of the effectiveness of AA for FXaI-associated GIB.

METHODS: This retrospective cohort study including consecutive patients receiving AA for FXaI-associated GIB (7/2018-2/2021). Demographics, blood product administration, hemostatic efficacy, rebleeding, thrombosis, and mortality rates were collected. Hemostatic efficacy (HE), based on corrected hemoglobin at 12 h compared to baseline, was categorized as excellent (<10% decrease), good (≤ 20% decrease), or poor (>20% decrease, > 2 units of additional coagulation intervention or death prior to repeat hemoglobin). Comparative transfusion requirements between efficacy groups was assessed by Wilcoxon-Rank test.

RESULTS: Twenty-two patients were included (64% male, median (IQR) age 76 years (67, 80). Most patients (59%, n = 13) were on apixaban, and the primary anticoagulation indication was atrial fibrillation (64%, n = 14). Median initial hemoglobin was 7.5 g/dL (IQR 6.4, 8.8) and 50% (n = 11) were upper GIB. Hemostatic efficacy was excellent in 46% (n = 10), good in 23% (n = 5), and poor in 32% (n = 7). There was no statistically significant difference in red blood cells (RBCs) received between those with excellent/good hemostasis (median 2, IQR 1 to 2) and those with poor hemostasis (median 4, IQR 1.5 to 4.5). Two patients (9%) had arterial thrombotic events within 30 days of reversal.

CONCLUSION: In this multicenter, single arm, real-world observational analysis of patients with factor Xa inhibitor associated GIB most patients achieved good hemostasis following administration of AA. There was a 9% 30-day thrombotic event rate. The lack of a control group limits the strength of the conclusions that can be drawn from this study.

来源:Am J Emerg Med,查看原文。版权归原作者所有。

参考来源

  1. Brown CS, Mattson AE, Cabrera D, et al. Real world utilization of Andexanet alfa in the management of oral factor Xa inhibitor-associated gastrointestinal bleeding. Am J Emerg Med. 2023. PMID: 37562071. doi:10.1016/j.ajem.2023.07.042

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。